Single-Shot hope for bowel disease tested in early trial
NCT ID NCT07029971
Summary
This early-stage study tested a new drug called BB-TL1A-VIAL-HLE to see if it is safe and might help people with moderate-to-severe ulcerative colitis. The trial involved 16 healthy volunteers and people with the condition, who received a single injection. Researchers monitored participants for about a year to check for side effects and early signs that the drug could reduce bowel inflammation and symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arcadia Pittwater Private Hospital (Operated by Battery Bio)
Warriewood, New South Wales, 2102, Australia
-
Dymocks Building, WellShare Site
Sydney, New South Wales, 2000, Australia
Conditions
Explore the condition pages connected to this study.